Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(2.70)
# 1,876
Out of 5,150 analysts
91
Total ratings
34.12%
Success rate
9.19%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XOMA XOMA Royalty | Initiates: Buy | $76 | $26.45 | +187.33% | 1 | Dec 9, 2025 | |
| SAVA Cassava Sciences | Initiates: Buy | $8 | $2.21 | +261.99% | 2 | Oct 6, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.65 | +3,900.00% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.38 | +3,094.04% | 1 | Dec 12, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $0.10 | +10,476.92% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $55.49 | -9.89% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.22 | +1,293.44% | 1 | Sep 30, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.06 | +1,220.75% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.70 | +2,381.48% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $43 | $21.43 | +100.65% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.93 | +265.11% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.03 | +628.16% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $3.69 | +306.50% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $7.05 | +439.01% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.82 | +4,778.05% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $7.07 | +607.21% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.51 | +3,529.76% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $15.99 | +106.38% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $19.86 | +101.41% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $0.22 | +16,919.32% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $7.77 | +311.84% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $7.58 | +915.83% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.42 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $65.10 | -23.20% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $5.20 | +535.23% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $11.59 | +124.33% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $265.00 | -89.43% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $4.97 | +17,002.62% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $11.04 | +90.22% | 2 | Jul 12, 2017 |
XOMA Royalty
Dec 9, 2025
Initiates: Buy
Price Target: $76
Current: $26.45
Upside: +187.33%
Cassava Sciences
Oct 6, 2025
Initiates: Buy
Price Target: $8
Current: $2.21
Upside: +261.99%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.65
Upside: +3,900.00%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.38
Upside: +3,094.04%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $0.10
Upside: +10,476.92%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $55.49
Upside: -9.89%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.22
Upside: +1,293.44%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.06
Upside: +1,220.75%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.70
Upside: +2,381.48%
Alto Neuroscience
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $21.43
Upside: +100.65%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $4.93
Upside: +265.11%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.03
Upside: +628.16%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $3.69
Upside: +306.50%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $7.05
Upside: +439.01%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.82
Upside: +4,778.05%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $7.07
Upside: +607.21%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.51
Upside: +3,529.76%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $15.99
Upside: +106.38%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $19.86
Upside: +101.41%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $0.22
Upside: +16,919.32%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $7.77
Upside: +311.84%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $7.58
Upside: +915.83%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.42
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $65.10
Upside: -23.20%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $5.20
Upside: +535.23%
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $11.59
Upside: +124.33%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $265.00
Upside: -89.43%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $4.97
Upside: +17,002.62%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $11.04
Upside: +90.22%